lenalidomide has been researched along with amg531 in 7 studies
Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (amg531) | Trials (amg531) | Recent Studies (post-2010) (amg531) |
---|---|---|---|---|---|
3,532 | 725 | 2,850 | 713 | 94 | 607 |
Protein | Taxonomy | lenalidomide (IC50) | amg531 (IC50) |
---|---|---|---|
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 8.27 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6605 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.1 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
Sekeres, MA | 1 |
Carraway, HE; Gore, SD; Loaiza-Bonilla, A | 1 |
Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B | 1 |
Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
Patel, BJ; Sekeres, MA | 1 |
Berdeja, J; Bhagat, P; Braunschweig, I; Donnellan, WB; Fehn, K; Goldfinger, M; Gonzalez-Lugo, JD; Gritsman, K; Jasra, S; Kambhampati, S; Kazemi, M; Kim, M; Kornblum, N; Mantzaris, I; Pradhan, K; Remy, C; Shah, N; Shastri, A; Sica, RA; Steidl, U; Verma, A; Will, B; Yacoub, A | 1 |
5 review(s) available for lenalidomide and amg531
Article | Year |
---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.
Topics: Antineoplastic Agents; Benzoates; Enzyme Inhibitors; Humans; Hydrazines; Lenalidomide; Methyltransferases; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Thalidomide; Treatment Outcome | 2010 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Lowering the boom on lower-risk myelodysplastic syndromes.
Topics: Activin Receptors, Type II; Aged; Antilymphocyte Serum; Benzoates; Bone Marrow Cells; Female; Hematinics; Humans; Hydrazines; Immunoglobulin Fc Fragments; Lenalidomide; Mutation; Myelodysplastic Syndromes; Pyrazoles; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia | 2019 |
1 trial(s) available for lenalidomide and amg531
Article | Year |
---|---|
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Hemorrhage; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome | 2023 |
1 other study(ies) available for lenalidomide and amg531
Article | Year |
---|---|
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis | 2014 |